Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA4Ag vaccine in healthy adults
NCT02364596Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of domagrozumab in Staphylococcus aureus infection, sponsored by Pfizer. Primary endpoints: Number of subjects reporting local reactions at 10 days, Number of subjects reporting systemic events at 10 days and 3 more. Started Jan 2015; status: completed.
02
Drugs
domagrozumab
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT02364596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364596.